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Abstract
Background: Low birth weight (LBW) is associated with increased future risk of insulin resistance and type 2 diabetes
mellitus. The underlying molecular mechanisms remain poorly understood. We have previously shown that young LBW men
have reduced skeletal muscle expression of PI3K p85a regulatory subunit and p110b catalytic subunit, PKCf and GLUT4 in
the fasting state. The aim of this study was to determine whether insulin activation of the PI3K/Akt and MAPK signalling
pathways is altered in skeletal muscle of young adult men with LBW.
Methods: Vastus lateralis muscle biopsies were obtained from 20 healthy 19-yr old men with BW,/ = 10th percentile for
gestational age (LBW) and 20 normal birth weight controls (NBW), matched for physical fitness and whole-body glucose
disposal, prior to (fasting state) and following a 4-hr hyperinsulinemic euglycemic clamp (insulin stimulated state).
Expression and phosphorylation of selected proteins was determined by Western blotting.
Principal Findings: Insulin stimulated expression of aPKCf (p,0.001) and Akt1 (p,0.001) was decreased in muscle of LBW men
when compared to insulin stimulated controls. LBW was associated with increased insulin stimulated levels of IRS1 (p,0.05), PI3K
p85a (p,0.001) and p110b (p,0.05) subunits, while there was no significant change in these proteins in insulin stimulated control
muscle. In addition LBW had reduced insulin stimulated phospho-Akt (Ser 473) (p,0.01), indicative of reduced Akt signalling.
Insulin stimulated expression/phosphorylation of all the MAPK proteins studied [p38 MAPK, phospho-p38 MAPK (Thr180/Tyr182),
phospho-ERK (Thr 202/Tyr204), JNK1, JNK2 and phospho-JNK (Thr 183/Tyr185)] was not different between groups.
Conclusions: We conclude that altered insulin activation of the PI3K/Akt but not the MAPK pathway precedes and may
contribute to development of whole-body insulin resistance and type 2 diabetes in men with LBW.
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Introduction
Developmental programming is the concept whereby nutrition-
al or environmental stimuli, acting during critical windows in
development, may have a lasting impact on cellular structure and
function, and consequently, on patterns of disease [1]. Low birth
weight (LBW), a surrogate marker of an adverse fetal environment,
is associated with development of insulin resistance and type 2
diabetes [2]. However, the underlying molecular mechanisms
remain poorly understood.
Skeletal muscle accounts for the majority of insulin-stimulated
glucose disposal [3], and defects in muscle insulin action represent an
early marker for diabetes risk [4]. Healthy individuals with LBW
have reduced muscle mass [5] and have recently been demonstrated
to have altered fibre composition in vastus lateralis muscle [6],
implying a role for skeletal muscle in the pathogenesis of insulin
resistance in LBW.Moreover, young LBWmen with normal glucose
tolerance and normal whole-body glucose disposal have reduced
forearm (muscle) glucose uptake following acute local insulin infusion
[7] and decreased fasting expression of key insulin signalling proteins
in vastus lateralis muscle [8], further supporting this concept.
Insulin signalling is mediated by a highly complex network
controlling a variety of different processes. Briefly, in the presence
of insulin, the insulin receptor phosphorylates insulin receptor
substrate (IRS) proteins, which are linked to the activation of two
main signalling pathways: the metabolic phosphatidylinositol 3
kinase (PI3K)/ protein kinase B (Akt, also known as PKB)
pathway, responsible for most of insulin’s metabolic actions, and
the mitogenic Ras-mitogen-activated protein kinase (MAPK)
pathway, which is involved in mediating cell growth, survival
and differentiation [9]. We have previously shown that young
LBW men have reduced skeletal muscle expression of PI3K p85a
regulatory subunit and p110b catalytic subunit, atypical protein
kinase C f (aPKCf) and glucose transporter (GLUT4) in the
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fasting state [8]. These changes precede the development of whole
body insulin resistance and glucose intolerance. However, it
remains to be determined whether the adverse fetal environment
leads to alterations in the expression of proteins in MAPK
signalling pathway. Insulin can activate three major members of
the MAPK family, including p38 MAPK [10,11], c-jun NH2-
terminal kinase (JNK) [12] and extracellular signal-regulated
kinase 1/2 (ERK1 and ERK2) [9]. Studies have indicated that p38
MAPK is required for full GLUT4 translocation [13] and aberrant
p38 MAPK signalling in skeletal muscle has been described in type
2 diabetic patients [10]. JNK activity is increased in insulin-
resistant states such as obesity and inflammation and can
negatively regulate insulin signalling through serine phosphoryla-
tion of IRS-1 and impaired activation of Akt [14]. ERK1 and
ERK2 may also be involved in a negative feedback loop of insulin
action by phosphorylating IRS-1 on serine residues [9].
Thus, the goal of this study was to determine whether altered
insulin activation of the PI3K/Akt and MAPK signalling pathways
could contribute to the development of insulin resistance and type 2
diabetes in LBW humans. To that end, we recruited 20 healthy 19
year old men with LBW and 20 normal birth weight (NBW) controls.
All subjects had normal glucose tolerance and whole-body insulin
sensitivity and were matched for physical fitness. Muscle biopsies
were obtained prior to and following a 4-hour hyperinsulinemic
euglycemic clamp and expression, and phosphorylation of key
insulin signaling proteins was determined by Western blotting.
Materials and Methods
Subjects and study protocol
Forty singleton men born at term (39–41 weeks) in 1980 in
Copenhagen County were recruited from the Danish Medical
Birth Registry according to birth weight, as previously described
[15]. Twenty men had birth weights ,/= the 10th percentile
(LBW: 27026202 g) and 20 men had birth weights in the upper
normal range (NBW: 50–75th percentile) (38016101 g). None of
the participants had a family history of diabetes (parents,
grandparents), hypertension, or ischemic heart disease. All
participants had normal glucose tolerance, as assessed by standard
75-gram OGTT, according to World Health Organization
criteria. Subjects meeting these criteria were included consecu-
tively and we made no specific attempts to match groups for body
composition etc. Written informed consent was provided from all
participants and approval was obtained from the regional ethics
committee. All subjects had DEXA assessment of body compo-
sition and assessment of aerobic fitness using a submaximal
VO2max test, as previously described [15]. On the study day,
following a 24 hr standardized diet and exercise protocol, a 2-hr
basal period and a standard 30-min intravenous glucose tolerance
test, all subjects underwent a 4-hr two-step hyperinsulinemic
euglycemic clamp (2 hrs at 10 mU/m2/min (low peripheral
hyperinsulinemia) and 2 hrs at 40 mU/m2/min (prandial-like
hyperinsulinemia) in combination with tritiated glucose tracer and
indirect calorimetry, as previously described [15]. Muscle biopsies
were excised at the end of the basal (+2 hrs after initiation of study)
and insulin-stimulated steady state period (+4 hrs after initiation of
insulin infusion).
Muscle Biopsies
Percutaneous muscle biopsies were obtained from the vastus
lateralis muscle during local anaesthesia using a Bergstrøm needle.
Samples were blotted free of blood, connective tissue and visible
fat, snap-frozen in liquid nitrogen and stored at 280uC until
further analysis.
Western blotting
Muscle biopsies were extracted in ice-cold lysis buffer
[50 mmol/l HEPES (pH 8), 150 mmol/l sodium chloride, 1%
Triton X100, 1 mmol/l sodium orthovanadate, 30 mmol/l sodium
fluoride, 10 mmol/l sodium pyrophosphate, 10 mmol/l EDTA
and a protease inhibitor cocktail]. The total protein concentration
in the lysates was determined using a Sigma copper/bicinchoninic
assay. Protein content of muscle tissue did not differ between any of
the groups. Samples were diluted to a common concentration of
1 mg/ml in Laemmli buffer and 20 ug total protein was subjected
to SDS-PAGE. The proteins were transferred to PVDF Immobi-
lon-P (Millipore) membrane, blocked for 1 hr (5% nonfat
dehydrated milk, 16TBS, 0.1% Tween 20), followed by overnight
incubation with antibody against IRS-1 and PI3K p85a (Upstate
Biotechnology, Lake Placid, USA); Akt1, Akt2, phospho-Akt
(Ser473) (all Cell Signalling Technology, Beverly, USA); PKCf,
PI3K p110b (Santa Cruz Biotechnology, Santa Cruz, USA),
phospho-ERK1/2 (Thr202/Tyr204), p38 MAP-kinase, phospho-
p38 MAP-kinase (Thr180/Tyr182), JNK1, JNK2 (all Cell
Signalling Technology, Beverly, USA); phospho-JNK (Thr183/
Tyr185) and GLUT4 (both Abcam, Cambridge, UK) diluted in
TBS–0.1% Teen 20 containing 5% dried milk or 5% BSA. Protein
expression was quantified densitometrically using AlphaEase
software (AlphaInnotech, San Leandro, USA). 20 mg and 10 mg
of one sample was loaded onto each gel in order to ensure the
linearity of the signal and to act as an inter-gel control.
Due to the limited size of the biopsy two strategies were used to
analyse protein expression. The first strategy was used for the
analysis of proteins that have not been previously analysed under
basal conditions: IRS-1, Akt2, phospho-Akt, p38 MAPK, phospho-
p38 MAPK, JNK1, JNK2, phospho-JNK, phospho-ERK1. Three
gels were used for the analysis of each protein, each gel containing six
samples randomly chosen from the four study groups. For the
analysis of PI3K p85a, PI3K p110b, PKCf, Akt1 and GLUT4,
which have been analysed under basal conditions previously, insulin-
stimulated NBW and LBW muscle samples were run on two gels
alongside 6 basal NBW samples (mean % control +/21 STD)
chosen on the basis of the previous study (8). For each antibody,
control blots were performed in which varying amounts of protein
(5 mg, 10 mg and 20 mg) were loaded onto the gel to ensure that the
chemiluminescent signal changed in a linear manner. Primary and
secondary antibody concentrations were also optimized.
Statistical analyses
Differences between individual baseline characteristics were
analyzed by Student’s t-test or non-parametrical tests (Wilcoxon,
Mann-Whitney) when appropriate (Table 1). Nonparametric data
were log transformed prior to testing and are shown as the %
geometric mean basal control (95% confidence intervals).
Parametric data are represented as % mean basal control6SEM.
Differences in insulin stimulation between the two birth weight
groups were analyzed using a two-way repeated measurement
ANOVA with birth weight and insulin-stimulation as the
independent variables, followed by Duncan’s Post Hoc test when
appropriate (Statistica 7.1, Statsoft, Tulsa, USA). For all data sets,
a p-value ,0.05 was considered statistically significant.
Results
Clinical characteristics (Table 1)
Demographic and metabolic data [15], fibre composition [6]
and expression of select proteins in vastus lateralis muscle in the
fasting state [8] have been reported previously. These studies
showed that 19-yr old men with LBW (,10th percentile) had
Altered PI3K/Akt in LBW
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comparable current body weight, BMI, W/H-ratio, VO2max and
total lean and fat mass with the NBWmen, but were slightly shorter
and had a tendency towardmore central fat accumulation (as shown
by the increased ratio of abdominal fat mass/total fat mass p,0.05).
LBW was associated with a higher proportion of ‘‘glycolytic’’ type
26 (formerly 2b) fibres at the expense of fewer but larger
‘‘oxidative’’ type IIa fibres. In addition, the LBW men had slightly
higher fasting plasma glucose and reduced insulin-stimulated whole-
body glycolytic flux but normal whole-body glucose disposal,
glucose oxidation, non-oxidative glucose metabolism and energy
expenditure in the fasting and insulin-stimulated state.
Protein expression-basal (fasting) state (Fig. 1 and
Table 2)
Fasting expression of the PI3K p85a and p110b subunits, PKCf
and GLUT4 was reduced in LBW subjects when compared to
controls, as previously reported (8) (Figure 1). Expression/phosphor-
ylation of other proteins studied involved in metabolic pathway
[(IRS1, Akt1, Akt2 and phospho-Akt (Ser 473)] or mitogenic
pathway [p38 MAPK, phospho-p38 MAPK (Thr180/Tyr182),
JNK1, JNK2, phospho-JNK (Thr 183/Tyr185) and phospho-ERK
(Thr202/Tyr204)] was unchanged in LBW subjects in fasting state
in comparison to the controls [Figure 1 and Table 2].
Protein expression–insulin-stimulated state (Fig. 1)
(1) IRS1 and PI3K. Insulin infusion (4 hrs) per se did not lead
to changes in expression of IRS1 in muscle of control subjects
however LBW demonstrated enhanced expression for IRS-1
under insulin stimulated conditions (p,0.01) (interaction between
birth weight and presence of insulin p,0.01) (Fig. 1A). Similarly,
expression of PI3K p85a (Fig. 1B) and p110b (Fig. 1C) did not
change upon insulin infusion in controls but despite lower basal
(fasting) expression LBW men had significantly increased p85a
(p,0.001) and p110b (p,0.001) after insulin infusion (interaction
between birth weight and insulin infusion p,0.001 for both PI3K
subunits). In addition the expression of both PI3K subunits was
significantly increased in insulin stimulated LBW subjects in
comparison to the insulin stimulated controls (for p85a p,0.001
and for p110b p,0.05).
(2) Akt. There was an interaction between birth weight and
insulin infusion on Akt1 expression (p,0.001). Insulin infusion
significantly increased expression of Akt1 (p,0.001) in control
subjects but it decreased expression of Akt1 in LBW men (p,0.05)
(Fig. 1D). No differences were observed between groups in Akt2
expression (Fig. 1E). There was an interaction between birth
weight and insulin infusion on phosphorylation of Akt at Ser 473
(p,0.05) (Fig. 1F). Insulin infusion significantly increased
phosphorylation of Akt (Ser 473) in both control (p,0.001) and
LBW groups (p,0.001), however the effect was greater in controls
when compared to the LBW men (p,0.01).
(3) PKCf and GLUT4. There was an interaction between
birth weight and insulin infusion on PKCf expression (p,0.001).
Insulin infusion significantly increased expression of PKCf in
control subjects (p,0.001), however no significant difference was
observed in LBW subjects (Fig. 1G). There was significant
reduction in PKCf expression in LBW men upon insulin
stimulation when compared to insulin stimulated control subjects
(p,0.001). Interestingly, insulin infusion had very different effect
on GLUT4 expression. Insulin infusion lead to reduction in
expression of GLUT4 (p,0.001) (Fig 1H) in controls, while
significant increase occurred in LBW men (p,0.05). Despite lower
basal (fasting) expression (p,0.01), insulin-stimulated expression of
GLUT4 was increased in LBW men in comparison to controls
(p,0.001). Interaction between birth weight and insulin
stimulation on GLUT4 expression was significant (p,0.001).
(4) Mitogenic proteins. There were no differences in the
expression/phosphorylation of p38 MAPK, phospho-p38 MAPK
(Thr180/Tyr182), JNK1, JNK2, phospho-JNK (Thr 183/Tyr185)
and phospho-ERK (Thr202/Tyr204) (Table 2).
Discussion
We have previously shown that young and healthy, low birth
weight men, exhibit multiple abnormalities in their skeletal muscle
in the insulin signalling metabolic pathway downstream of the
insulin receptor, under fasting conditions [8]. In this study we
aimed to investigate whether any further alterations in either
mitogenic (MAPK) or metabolic (PI3K/Akt) pathways down-
stream of insulin receptor can be detected in skeletal muscle in
response to in vivo insulin stimulation that could explain why are
LBW men at higher risk of developing insulin resistance and type 2
diabetes in later life. The main finding of this study is marked
insulin-mediated up-regulation in LBW subjects of the PI3K p85a
and p110b subunits and reduced expression/phosphorylation of
its two main effectors, PKCf and phospho-Akt at Ser 473, both of
which are required for insulin-stimulated glucose uptake [9,16].
Previously, we have reported reduced abundance of p85a,
p110b, PKCf and GLUT4 proteins in skeletal muscle of LBW
men under fasting conditions [8]. Similar reductions of p85a,
p110b and GLUT4 were observed in subcutaneous abdominal fat
biopsies from an independent LBW cohort, together with a
marked reduction of IRS-1 [17]. IRS molecules are key mediators
of insulin signalling and play a central role in maintaining basic
cellular functions such as growth, survival and metabolism. Using
siRNA (small interfering RNA)- mediated knockdown of IRS
proteins, it was found that IRS-1, rather than IRS-2 is required for
insulin-stimulated Akt1 phosphorylation, GLUT4 translocation
and glucose uptake [18,19]. Here we show that skeletal muscle
IRS-1 expression was similar in control and LBW men. This is
consistent with previous reports of normal IRS1 expression in the






Birth weight (g) 27026202 3801 6101 ,0.0001
Height (cm) 178.564.0 181.764.8 0.03
Weight (kg) 73.668.5 74.7613.1 NS
BMI (kg/m2) 23.162.7 22.663.6 NS
W/H-ratio 0.8260.04 0.8160.06 NS
Total lean mass DEXA (kg) 54.964.3 56.967.3 NS
Total fat mass DEXA (kg) 15.566.8 15.666.9 NS
Abdominal fat mass DEXA (kg) 33.1618.1 30.7621.9 NS
VO2max (L/mol) 3.460.4 3.560.7 NS
f-pl-glc (mmol/L) 5.660.4 5.460.4 0.05
f-pl-ins (pmol/L) 56.1639.6 48.6622.2 NS
Rd 40mU (mg/kg FFM/min) 11.163.1 11.963.0 NS
Rd 40mU (mg/kg FFM/min) 3.962.6 5.462.6 0.04
Differences between individual baseline characteristics were analyzed by
Student’s t-test, or non-parametrical tests (Wilcoxon, Mann-Whitney) when
appropriate. p-value ,0.05 was considered statistically significant.
doi:10.1371/journal.pone.0003738.t001
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skeletal muscle from diabetic subjects [20]. We also show that
insulin-stimulated expression of IRS-1 was increased in LBW men
but not in controls. Recent studies in L6 myotubes showed that,
prior to its down-regulation by degradation, IRS-1 protein is
acutely induced by insulin stimulation [21]. Thus, the inappro-
priately increased IRS-1 in LBW at 4 h of insulin stimulation may
be a consequence of delayed/protracted stimulation and/or
delayed degradation.
Figure 1. Expression and phosphorylation of key proteins involved in PI3K signalling. Bars represent mean basal and insulin-stimulated
(INS) expression values6SEM for low birth weight (LBW) and control (CON) individuals, expressed as % of mean control. Representative blots of the
respective proteins are located below the corresponding bar graphs. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0003738.g001
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Despite lower expression in the basal state, insulin stimulation
increased expression of PI3K subunits p110b and p85a in LBW
subjects but not in controls. The mechanistic basis of this
paradoxical increase following insulin infusion is unknown.
Increased expression of p85a has been implicated in insulin
resistance as knockout of p85a improves insulin sensitivity in vitro
[22] and in vivo [23]. Conversely, over-expression of p85a is
correlated with skeletal muscle insulin resistance in obesity and
type 2 diabetes [24] and has been reported in insulin-resistant
states induced by e.g. growth hormone excess [25] and short-term
overfeeding [26]. It is thought that excess p85a may exert these
effects by sequestration of IRS-1 and PI3K enzymatic activity into
inert cellular foci incapable of PI-3, 4, 5-triphosphate (PIP3)
generation [27].
PI3K is thought to mediate many of its metabolic actions of
insulin through phosphorylation of Akt. Phosphorylation of Akt at
Ser473 was reduced in the LBW group compared to controls
following insulin infusion, suggesting impaired PI3K activity.
Limited sample availability meant that actual activity could not be
determined. Decreased insulin stimulated Akt kinase activity has
been previously reported in type 2 diabetic subject [28,29] and
non-obese spontaneously diabetic Goto-Kakizaki (GK) rats [30].
As well as a reduction in PI3K activity, reduced Akt1 expression
could also contribute to reduction in phospho-Akt detected in the
insulin stimulated LBW muscle. However, Akt2 is the prominent
isoform in skeletal muscle [31,32] thus phosphorylated Akt
detected primarily represents phospho-Akt2. Our findings of no
difference in the basal and insulin stimulated expression of Akt2
between control and LBW confirm previous finding that insulin
stimulation has no effect on total Akt expression [29]. Knockout
and siRNA studies have revealed that whereas Akt2 is indispens-
able for glucose homeostasis, Akt1 is essential for growth and may
play a role in lipid metabolism [9,33]. Decreased Akt1 levels in
LBW may reflect a general resistance to stimulation by growth
factors and combined with our findings in the basal state, could
contribute to the reduced muscle mass observed in LBW men.
In addition to decreased phosphorylation of phospho-Akt we
have also found significant reduction in the expression of PKCf in
LBW subjects. Activation of PKC isoforms l and f is required for
GLUT4 translocation and glucose uptake in the insulin stimulated
state [34–36]. This is supported by reports showing that over-
expression of a dominant-negative mutant of PKCf in muscle cells
leads to abrogation of insulin-stimulated glucose transport and
GLUT4 translocation [37,38], while over-expression of PKCf in
skeletal muscle in vivo enhanced both basal and insulin-stimulated
glucose transport [39]. The importance of PKCf in pathogenesis
of insulin resistance in vivo has been suggested by numerous studies
showing impaired activation of PKCf in skeletal muscle in obese
subjects [40], impaired glucose tolerance [41], type 2 diabetes
[40,41] and in a rat model of intrauterine growth restriction
(IUGR)[42]. Here we show that LBW men have diminished basal
and insulin stimulated expression of PKCf, which would provide
less substrate for full activation.
GLUT4 levels, despite being lower under basal conditions were
paradoxically increased by insulin infusion in LBW men. Thus,
while insulin-stimulation reduced total GLUT4 in the control
subjects, consistent with two previous reports [43,44], no such
effect was observed in LBW men. Interestingly, a similar lack of
response to insulin was also observed in type 2 diabetes patients
[43] and following insulin resistance induced by lipid infusion [44],
indicating that this phenomenon may indeed be related to insulin
resistance. Consistent with our previous observations in humans
[8], it was recently shown that adult rat IUGR offspring have
reduced GLUT4 abundance in muscle in the basal state [45].
Moreover, redistribution of GLUT4 from intracellular compart-
ments to the plasma membrane in the basal state was partly
responsible for a total inability of GLUT4 to respond to insulin
[45]. Thus, it is possible that the higher insulin-stimulated GLUT4
protein levels observed in our LBW subjects do not translate into
increased GLUT4 translocation and improved glucose disposal.
Following reports of aberrant p38 MAPK signalling in skeletal
muscle of type 2 diabetic patients [10] and increased phosphor-
ylation and activity of p38 MAPK upon hyperglycaemia in
cultured L6 myotubes [46] we decided to asses whether insulin
action upon mitogenic signalling pathway can be also implicated
in the pathogenesis of type 2 diabetes in LBW men. Insulin
stimulated expression/phosphorylation of all the MAPK proteins
studied p38 MAPK, phospho-p38 MAPK (Thr180/Tyr182),
phospho-ERK (Thr 202/Tyr204), JNK1, JNK2 and phospho-
JNK (Thr 183/Tyr185) was not different between NBW and LBW
groups studied. Therefore we can conclude that key proteins
involved in MAPK signalling pathway do not contribute to
alterations observed in skeletal muscle of young LBW men [6]. It is
possible that the changes reported in p38 MAPK signalling in type
2 diabetic patients are a consequence of diabetes and may develop
in LBW as their glucose homeostasis deteriorates.
In summary, we have demonstrated that LBW, a known risk
factor for development of insulin resistance and type 2 diabetes, is
associated with multiple defects in the PI3K/Akt pathway under
basal conditions and following in vivo insulin-stimulation. Given
that these were young healthy subjects, matched for total body fat,
VO2max and whole-body insulin sensitivity, we speculate that
these are primary defects, likely to contribute to the pathogenesis
of skeletal muscle loss and development of muscle insulin
Table 2. Expression and phosphorylation of key proteins involved in MAPK-signalling.
Protein expression/phosphorylation Control Control Insulin stimulated LBW LBW Insulin stimulated
p-ERK (Thr202/Tyr204) 100 [15–228] 117 [26–303] 129 [35–349] 119 [49–407]
p-p38 (Thr180/Tyr182) 100 [11–220] 61 [0–262] 71 [5–182] 46 [32–247]
p38 10068 10268 110617 107614
p-JNK (Thr183/Tyr185) 10069 87610 100611 10969
JNK1 10067 135614 117614 11967
JNK2 10067 10468 10469 9566
Values are presented as the geometric mean basal control [95% confidence limits] for p-ERK (Thr202/Tyr204) and p-p38 (Thr180/Tyr182) and as the % mean basal
control6SEM for p38, p-JNK (Thr183/Tyr185), JNK1 and JNK2. Statistical differences were analysed using a repeated measures ANOVA. Data for p-ERK (Thr202/Tyr204)
and p-p38 (Thr180/Tyr182) were log transformed prior to testing.
doi:10.1371/journal.pone.0003738.t002
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resistance associated with LBW. Prospective studies are needed to
establish the significance and/or reversibility of these findings.
Acknowledgments
We wish to express our gratitude to all the human volunteers without
whom this study would not have been possible.
Author Contributions
Conceived and designed the experiments: CBJ HS SM AV SEO.
Performed the experiments: CBJ MSMG HS. Analyzed the data: CBJ
MSMG. Contributed reagents/materials/analysis tools: CBJ MSMG
SEO. Wrote the paper: CBJ MSMG SEO.
References
1. Gluckman PD, Hanson MA, Beedle AS (2007) Early life events and their
consequences for later disease: a life history and evolutionary perspective.
Am J Hum Biol 19: 1–19.
2. McMillen IC, Robinson JS (2005) Developmental origins of the metabolic
syndrome: prediction, plasticity, and programming. Physiol Rev 85: 571–633.
3. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J (1985) Effects
of insulin on peripheral and splanchnic glucose metabolism in noninsulin-
dependent (type II) diabetes mellitus. J Clin Invest 76: 149–155.
4. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, et al. (1992)
Role of glucose and insulin resistance in development of type 2 diabetes mellitus:
results of a 25-year follow-up study. Lancet 340: 925–929.
5. Kensara OA, Wootton SA, Phillips DI, Patel M, Jackson AA, et al. (2005) Fetal
programming of body composition: relation between birth weight and body
composition measured with dual-energy X-ray absorptiometry and anthropo-
metric methods in older Englishmen. Am J Clin Nutr 82: 980–987.
6. Jensen CB, Storgaard H, Madsbad S, Richter EA, Vaag AA (2007) Altered
Skeletal Muscle Fiber Composition and Size Precede Whole-body Insulin
Resistance in Young Men with Low Birth Weight. J Clin Endocrinol Metab 92:
1530–1534.
7. Hermann TS, Rask-Madsen C, Ihlemann N, Dominguez H, Jensen CB, et al.
(2003) Normal insulin-stimulated endothelial function and impaired insulin-
stimulated muscle glucose uptake in young adults with low birth weight.
J Clin.Endocrinol Metab 88: 1252–1257.
8. Ozanne SE, Jensen CB, Tingey KJ, Storgaard H, Madsbad S, et al. (2005) Low
birthweight is associated with specific changes in muscle insulin-signalling
protein expression. Diabetologia 48: 547–552.
9. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling
pathways: insights into insulin action. Nat Rev Mol Cell Biol 7: 85–96.
10. Koistinen HA, Chibalin AV, Zierath JR (2003) Aberrant p38 mitogen-activated
protein kinase signalling in skeletal muscle from Type 2 diabetic patients.
Diabetologia 46: 1324–1328.
11. Zarubin T, Han J (2005) Activation and signaling of the p38 MAP kinase
pathway. Cell Res 15: 11–18.
12. Miller BS, Shankavaram UT, Horney MJ, Gore AC, Kurtz DT, et al. (1996)
Activation of cJun NH2-terminal kinase/stress-activated protein kinase by
insulin. Biochemistry 35: 8769–8775.
13. Furtado LM, Somwar R, Sweeney G, Niu W, Klip A (2002) Activation of the
glucose transporter GLUT4 by insulin. Biochem Cell Biol 80: 569–578.
14. Lee YH, Giraud J, Davis RJ, White MF (2003) C-Jun N-terminal kinase (JNK)
mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 278:
2896–2902.
15. Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S, et al. (2002) Early
differential defects of insulin secretion and action in 19-year- old Caucasian men
who had low birth weight. Diabetes 51: 1271–1280.
16. Farese RV, Sajan MP, Standaert ML (2005) Insulin-sensitive protein kinases
(atypical protein kinase C and protein kinase B/Akt): actions and defects in
obesity and type II diabetes. Exp Biol Med (Maywood) 230: 593–605.
17. Ozanne SE, Jensen CB, Tingey KJ, Martin-Gronert MS, Grunnet L, et al.
(2006) Decreased protein levels of key insulin signalling molecules in adipose
tissue from young men with a low birthweight-potential link to increased risk of
diabetes? Diabetologia 49: 2993–2999.
18. Huang C, Thirone AC, Huang X, Klip A (2005) Differential contribution of
insulin receptor substrates 1 versus 2 to insulin signaling and glucose uptake in l6
myotubes. J Biol Chem 280: 19426–19435.
19. Bouzakri K, Zachrisson A, Al-Khalili L, Zhang BB, Koistinen HA, et al. (2006)
siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-2/
Akt1 in glucose and lipid metabolism in human skeletal muscle. Cell Metab 4:
89–96.
20. Bjornholm M, Kawano Y, Lehtihet M, Zierath JR (1997) Insulin receptor
substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal
muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 46:
524–527.
21. Ruiz-Alcaraz AJ, Liu HK, Cuthbertson DJ, McManus EJ, Akhtar S, et al. (2005)
A novel regulation of IRS1 (insulin receptor substrate-1) expression following
short term insulin administration. Biochem J 392: 345–352.
22. Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, et al. (2003) Positive
and negative roles of p85 alpha and p85 beta regulatory subunits of
phosphoinositide 3-kinase in insulin signaling. J Biol Chem 278: 48453–48466.
23. Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, et al.
(2002) Reduced expression of the murine p85alpha subunit of phosphoinositide
3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 109:
141–149.
24. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM (2005) Increased p85/55/50
expression and decreased phosphotidylinositol 3-kinase activity in insulin-
resistant human skeletal muscle. Diabetes 54: 2351–2359.
25. Barbour LA, Mizanoor RS, Rahman S, Gurevich I, Leitner JW, et al. (2005)
Increased P85alpha is a potent negative regulator of skeletal muscle insulin
signaling and induces in vivo insulin resistance associated with growth hormone
excess. J Biol Chem 280: 37489–37494.
26. Cornier MA, Bessesen DH, Gurevich I, Leitner JW, Draznin B (2006)
Nutritional upregulation of p85alpha expression is an early molecular
manifestation of insulin resistance. Diabetologia 49: 748–754.
27. Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC (2005) The p85 regulatory
subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the
formation of a sequestration complex. J Cell Biol 170: 455–464.
28. Krook A, Roth RA, Jiang XJ, Zierath JR, Wallberg-Henriksson H (1998)
Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM
subjects. Diabetes 47: 1281–1286.
29. Cozzone D, Frojdo S, Disse E, Debard C, Laville M, et al. (2008) Isoform-
specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal
muscle cells from type 2 diabetic patients. Diabetologia 51: 512–521.
30. Kroook A, Kawano Y, Song XM, Efendic´ S, Roth RA, et al. (1997) Improved
glucose tolerance restores insulin-stimulated Akt kinase activity and glucose
transport in skeletal muscle from diabetic Goto-Kakizaki rats. Diabetes 46:
2110–2114.
31. Altomare DA, Lyons GE, Mitsuuchi Y, Cheng JQ, Testa JR (1998) Akt2 mRNA
is highly expressed in embryonic brown fat and the AKT2 kinase is activated by
insulin. Oncogene 16: 2407–2411.
32. Altomare DA, Guo K, Cheng JQ, Sonoda G, Walsh K, et al. (1995) Cloning,
chromosomal localization and expression analysis of the mouse Akt2 oncogene.
Oncogene 11: 1055–1060.
33. Bouzakri K, Zachrisson A, Al-Khalili L, Zhang BB, Koistinen HA, et al. (2006)
siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-2/
Akt1 in glucose and lipid metabolism in human skeletal muscle. Cell Metab 4:
89–96.
34. Kotani K, Ogawa W, Matsumoto M, Kitamura T, Sakaue H, et al. (1998)
Requirement of atypical protein kinase clambda for insulin stimulation of
glucose uptake but not for Akt activation in 3T3–L1 adipocytes. Mol Cell Biol
18: 6971–6982.
35. Sajan MP, Rivas J, Li P, Standaert ML, Farese RV (2006) Repletion of Atypical
Protein Kinase C following RNA Interference-mediated Depletion Restores
Insulin-stimulated Glucose Transport. J Biol Chem 281: 17466–17473.
36. Standaert ML, Galloway L, Karnam P, Bandyopadhyay G, Moscat J, et al.
(1997) Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-
kinase during insulin stimulation in rat adipocytes: potential role in glucose
transport. J Biol Chem 272: 30075–30082.
37. Bandyopadhyay G, Kanoh Y, Sajan MP, Standaert ML, Farese RV (2000)
Effects of adenoviral gene transfer of wild-type, constitutively active, and kinase-
defective protein kinase C-lambda on insulin-stimulated glucose transport in L6
myotubes. Endocrinology 141: 4120–4127.
38. Bandyopadhyay G, Standaert ML, Galloway L, Moscat J, Farese RV (1997)
Evidence for involvement of protein kinase C (PKC)-zeta and noninvolvement of
diacylglycerol-sensitive PKCs in insulin-stimulated glucose transport in L6
myotubes. Endocrinology 138: 4721–4731.
39. Etgen GJ, Valasek KM, Broderick CL, Miller AR (1999) In vivo adenoviral
delivery of recombinant human protein kinase C-zeta stimulates glucose
transport activity in rat skeletal muscle. J Biol Chem 274: 22139–22142.
40. Kim YB, Kotani K, Ciaraldi TP, Henry RR, Kahn BB (2003) Insulin-stimulated
protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with
obesity and type 2 diabetes: reversal with weight reduction. Diabetes 52: 1935–1942.
41. Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, et al. (2003)
Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-
(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance:
amelioration by rosiglitazone and exercise. Diabetes 52: 1926–1934.
42. Oak SA, Tran C, Pan G, Thamotharan M, Devaskar SU (2006) Perturbed
skeletal muscle insulin signaling in the adult female intrauterine growth-
restricted rat. Am J Physiol Endocrinol Metab 290: E1321–E1330.
43. Andersen PH, Lund S, Vestergaard H, Junker S, Kahn BB, et al. (1993)
Expression of the major insulin regulatable glucose transporter (GLUT4) in
skeletal muscle of noninsulin-dependent diabetic patients and healthy subjects
before and after insulin infusion. J Clin Endocrinol Metab 77: 27–32.
44. Handberg A, Vaag A, Beck-Nielsen H, Vinten J (1992) Peripheral glucose
uptake and skeletal muscle GLUT4 content in man: effect of insulin and free
fatty acids. Diabet Med 9: 605–610.
Altered PI3K/Akt in LBW
PLoS ONE | www.plosone.org 6 November 2008 | Volume 3 | Issue 11 | e3738
45. Thamotharan M, Shin BC, Suddirikku DT, Thamotharan S, Garg M, et al.
(2005) GLUT4 expression and subcellular localization in the intrauterine
growth-restricted adult rat female offspring. Am J Physiol Endocrinol Metab
288: E935–E947.
46. Huang C, Somwar R, Patel N, Niu W, Torok D, et al. (2002) Sustained exposure
of L6 myotubes to high glucose and insulin decreases insulin-stimulated GLUT4
translocation but upregulates GLUT4 activity. Diabetes 51: 2090–8.
Altered PI3K/Akt in LBW
PLoS ONE | www.plosone.org 7 November 2008 | Volume 3 | Issue 11 | e3738
